Le Lézard
Classified in: Health
Subject: PER

Impopharma Inc. Strengthens Management Team and Board of Directors



TORONTO, Oct. 5, 2017 /PRNewswire/ -- Impopharma Inc. today announced the following organizational changes:

In his new role, Mr. Mayers will provide strategic leadership and assume responsibility for day-to-day operations of the organization. He brings 27 years of pharmaceutical experience; most recently as President and founder of Maycore Inc., a business development and consulting solutions company, and previously Managing Partner of Pharm Eng. Technologies. Prior to this, Mr. Mayers was President of WellSpring Pharma Services, where he managed strategic and operational aspects of the CDMO organization. Previously, Mr. Mayers was Vice President Manufacturing Operations at Purdue Pharma, where he managed significant facility expansions and engineered the launch and line extension of such major brands as Targin, Biphentin and OxyNEO. Mr. Mayers also has held leadership positions in Manufacturing, Quality, Research & Development, Operations, Project Management and Strategy for Apotex, Merck KGaA, Taro and SmithKline Beecham.

Mr. Mayers holds an Hons. BSc. Degree in Biological Sciences from the University of Guelph and an MBA from the Rotman School of Business, University of Toronto.

Dr. Odlaug, Impopharma's Executive Chairman, stated "David's extensive experience in the pharmaceutical industry, specifically in the areas of product development and analytical R&D coupled with his in-depth knowledge of the CDMO space make him the ideal person to help build out future."

David Brown joins Impopharma from Teva Ltd, where he was Director, R&D Program Management with responsibility for portfolio selection, project management and technical expertise. Previously, he was Director, Pharmaceutical Development. Dr. Brown began his career in the UK in respiratory drug development at Fisons Plc. After moving to Canada, he worked at RTP Pharma and Patheon Inc.

Dr. Brown holds an Hons. Bachelor of Pharmacy and a Ph.D. in Pharmaceutics from the School of Pharmacy, University of London, United Kingdom.

"We are pleased to announce, David Brown has assumed the role of Senior Director R&D overseeing all aspects of R&D including formulation, product development and analytical services," said Mr. Mayers. "Dr. Brown brings not only over 20 years of experience in project management and product development but his formulation experience in respiratory device products positions us well to serve our clients and develop future projects."

Wayne Kreppner was most recently President and Chief Operating Officer at Concordia International. Mr. Kreppner brings over 20 years of experience as a pharmaceutical operations and R&D executive. A co-founder and former Vice-President of Product Development at Trimel Pharmaceuticals, Mr. Kreppner was responsible for all scientific operations including R&D, clinical development, manufacturing and supply chain. From 1997 to 2008 Mr. Kreppner held various senior roles in operations and regulatory affairs with Biovail Corporation.

Mr. Kreppner holds a Hons. B.Sc. degree in Biochemistry from the University of Western Ontario, an M.Sc. in Medical Science from McMaster University and an MBA from the Ivey School of Business, University of Western Ontario.

Dr. Odlaug noted that "Wayne Kreppner brings a proven track record of experience in the pharmaceutical industry and will further enhance our strategic leadership as a member of our Board."

About Impopharma

Impopharma is a well-resourced development and testing facility with an expert and experienced team located in Concord, Ontario, Canada that specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, and dermal products. Please visit
www.Impopharma.com.

Contact:
Impopharma Inc.
Vice President, Finance
Tel: (905) 760-0232
Vien Brewster

SOURCE Impopharma Inc.


These press releases may also interest you

at 15:30
DUBLIN, November 17, 2017 /PRNewswire/ -- The "Veterinary/Animal Vaccines Market by Type (Poultry, Companion Animal, Aquaculture), Disease (Porcine Parvovirus, Swine Pneumonia, Avian Influenza, Rabies, Clostridial Diseases), Technology (Inactivated,...

at 15:30
NEW YORK, Nov. 17, 2017 /PRNewswire/ -- This new 366-page report from LeadingMarketResearch.com contains 108 tables and provides analysis of the global respiratory disease testing market, including emerging tests, technologies, instrumentation, sales...

at 15:30
CARROLLTON, Texas, Nov. 17, 2017 /PRNewswire/ -- Hospice Source announced today that it has purchased Gainesville, Georgia-based Home Medical Professionals (HMP). This acquisition expands Hospice Source's geographical footprint into the greater...

at 15:29
OTTAWA, Nov. 17, 2017 /CNW/ - Health Canada is advising Canadians that the following products may pose serious health risks. For more information, including what Canadians should do, visit the online safety alert.    Unauthorized health...

at 15:28
BROOKLYN, N.Y., Nov. 17, 2017 /PRNewswire/ -- Dr. Bruce S. Hoffman is recognized by Continental Who's Who as a Pinnacle Professional Member in the field of Psychology in recognition of his role as Clinical Psychologist at Bruce S. Hoffman, Psy.D.  ...

at 14:46
SILVER SPRING, Md., Nov. 17, 2017 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a remote feature for follow-up programming sessions for the Nucleus Cochlear Implant System through a telemedicine platform. The remote...




News published on 5 october 2017 at 17:15 and distributed by: